Stockreport

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF 9 of 25 BriaCell patients treated since 2022 remain alive 18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar [Read more]